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Abstract From a subtracted cDNA library we have isolated a 
cDNA clone coding for a novel transformation-sensitive protein 
which is expressed by human fibroblasts, but not by their 
matched SV40 transformed counterparts. This protein has a 
molecular mass of 51 kDa and is highly related to the HtrA 
family of serine proteases from bacteria. At the N-terminal end, 
it contains an IGF-binding domain which may modulate the 
activity of the associated serine protease. Our data are consistent 
with the assumption that the novel protein represents one of the 
proteases that regulate the availability of IGFs by cleaving IGF- 
binding proteins. 
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factor binding protein; Serine protease; Subtractive cDNA 
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1. Introduction 
2. Materials and methods 
2.1. Cell culture 
Embryonic human lung fibroblasts (WI38) and their SV40 trans- 
formed counterparts (WI38-VA13) were purchased from the Ameri- 
can Type Culture Collection (Rockville, MD). The cells were culti- 
vated at 37°C under an atmosphere of 5% CO2 in Dulbecco's 
modified Eagle's Medium supplemented with 9% fetal calf serum, 
100 ~tg/ml streptomycin a d 100 U/ml penicillin. 
2.2. Northern blotting 
RNA was extracted from confluent cell layers by the SDS/protein- 
ase K method and purified on oligo(dT)-cellulose [1-3]. The samples 
(2 lag/lane) were resolved on a 1% agarose gel in the presence of 1 M 
formaldehyde and transferred toa Nylon membrane by vacuum blot- 
ting [3]. The membrane was hybridized overnight under standard 
conditions (42°C, 50% formamide) with a eDNA probe that had 
been labeled by the random primed oligolabeling method [4]. The 
blot was washed at regular stringency and exposed to X-ray film. 
The multiple tissue Northern blot used in this study contained poly(A) 
RNA (2 p,g/lane) from eight different human tissues (Clontech, Palo 
Alto, CA) and was processed as described above. 
Fibroblasts transformed by oncogenic viruses are often 
used by researchers as a model system to investigate he mo- 
lecular events that lead to immortalization and phenotypic 
transformation f tumor cells. Usually, such fibroblasts exhib- 
it dramatic alterations in their morphology, including a 
roundish shape, irregularities at,the cell surface and disinte- 
gration of the cytoskeleton. It is well accepted that these 
changes are caused by subtle alterations in the synthesis and 
degradation of proteins (transformation-sensitive proteins) 
that are involved, directly or indirectly, in cell adhesion and 
attachment. 
We have recently reported a novel approach to search for 
transformation-sensitive proteins [I]. Genes that were ex- 
pressed by normal fibroblasts, but not by their SV40 trans- 
formed counterparts, were selected by subtractive cDNA clon- 
ing. This approach led to the isolation of a dozen differentially 
expressed cDNA clones, many of which coded for known 
transformation-sensitive proteins, including fibronectin, col- 
lagen VI and vinculin. 
One of the clones obtained in this way was found to code 
for a novel serine protease. Here we present evidence that this 
protein might be involved in the cleavage of IGF-binding 
proteins. 
*Corresponding author. Fax: (41) (31) 632 4999. 
Abbreviations: DFP, diisopropyl f uorophosphate; IGF, insulin-like 
growth factor; IGFBP, insulin-like growth factor binding protein; 
RACE, rapid amplification ofcDNA ends. 
2.3. Screening of cDNA libraries 
A subtracted eDNA library was created with mRNA from human 
fibroblasts and their SV40 transformed counterparts by the biotin/ 
streptavidin/phenol method [1,5]. Clone L56 was used to screen two 
commercial cDNA libraries, one prepared from human fibroblasts 
(HL1011), the other prepared from human placenta (HL1075b, Clon- 
tech) by the plaque hybridization technique [3,6]. Positive clones were 
picked and subcloned into the plasmid pUC19. To obtain the 5'-end 
of the L56 mRNA, the AmpliFINDER RACE Kit (Clontech) was 
utilized in combination with several synthetic oligonucleotide primers 
that had been designed according to the 5' sequences of the cDNA 
clones. 
2.4. DNA sequencing 
The sequences of the cDNA inserts were determined on both 
strands by the dideoxy chain termination method [7] using Sequenase 
2.0 (USB, Cleveland, OH). The derived amino acid sequences were 
compared with all entries of the Swissprot databank (release 34.0) 
using the GCG Computer Program Package (University of Wisconsin, 
Madison, WI). 
3. Results 
3.1. Isolation of  cDNA clones 
Subtractive cDNA cloning starting from mRNA of normal 
and SV40 transformed fibroblasts yielded a dozen of differen- 
tially expressed cDNA clones. One of these clones, termed 
L56, was further investigated in this report. The insert of 
this clone hybridized to an mRNA of ~2300 nucleotides 
present iq normal human fibroblasts, but missing in their 
matched SV40 transformed counterparts (Fig. 1, left). As 
demonstrated on a Northern blot with RNA from eight dif- 
ferent human tissues, this mRNA was strongly expressed in 
placenta, moderately in brain, liver and kidney, and weakly in 
lung, skeletal muscle, heart and pancreas (Fig. 1, right). 
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Fig. 1. Northern blot analysis. RNA from human fibroblasts (W138), their SV40 transformed counterparts (VA13) and eight human tissues was 
resolved on agarose gels, transferred to Nylon membranes and hybridized with the radiolabeled insert of clone L56. The migration positions of 
standard RNAs are indicated in the margin. 
Since the insert of the original clone was only 228 bp long 
and did not show much similarity with any of the entries of 
the EMBL databank, it was used as a probe to screen two 
commercial cDNA libraries, one prepared from human fibro- 
blasts, the other from human placenta. 14 overlapping cDNA 
clones were found, but none contained the entire reading 
frame of the encoded protein. We therefore utilized the 
RACE technique to select clones that specifically contained 
the 5'-end of the mRNA. After several rounds of primer ex- 
tension and amplification by the polymerase chain reaction, 
16 additional cDNA clones were obtained. Altogether our 
clones covered ,~ 2100 bp. 
3.2. Nucleotide and derived amino acid sequence 
The combined cDNA sequence contained a G/C-rich 5' 
untranslated region of 38 bp (Fig. 2). The first ATG codon 
(positions 39-41) fulfilled the criteria of a typical start site for 
translation [8]. This start codon was followed by an open 
reading frame of 1440 bp which terminated in the stop codon 
TAG (positions 1479-1481). The 3' untranslated region was 
550 bp long and contained the sequence ATTAAA (positions 
2007-2012) that resembled the consensus signal AATAAA for 
polyadenylation. This signal was followed after 17 bp by a 
poly(A) tail of ,~ 80 nucleotides. 
The open reading frame could be translated into an amino 
acid sequence of 480 residues (Fig. 2). The predicted protein 
had a molecular mass of 51 kDa with a calculated isolectric 
point of 7.7. The sequence started with a typical signal peptide 
which represented the most hydrophobic portion of the entire 
protein on a hydrophilicity blot according to Kyte and Doo- 
little [9]. The rules of Von Heijne [10] predicted that this signal 
peptide was cleaved after alanine at position 22 with a score 
of 13.5. The mature product would therefore start with 
a glutamine residue which might spontaneously convert 
into pyroglutamic acid and block the N-terminus of the poly- 
peptide as observed with many extracellular matrix pro- 
teins. 
3.3. Similarity to other proteins 
A detailed comparison of the protein sequence with all en- 
tries of the Swissprot databank revealed a substantial similar- 
ity between the first 120 amino acid residues and the family of 
the IGF-binding proteins [11,12]. With IGFBP-3 the L56 pro- 
tein shared 44% sequence identity and this increased to 58% 
when conservative amino acid substitutions were included 
(Fig. 3, top). Comparable similarities were noted between 
the L56 protein and the other members of the IGFBP family. 
The aligned segment corresponded to a cluster of 12 cysteine 
residues that are conserved in all IGF-binding proteins. 11 of 
these cysteines were also found in the L56 sequence and the 
only cysteine that did not line up occurred in the L56 se- 
quence shifted by 7 residues. It is therefore likely that the 
N-terminus of the L56 protein represents an IGF-binding do- 
main. 
The C-terminal part of the L56 protein (amino acids 150- 
480) was found to be highly related to the family of the HtrA/ 
Do proteases from bacteria [13-15]. A comparison with the 
HtrA protease from E. coli (Fig. 3, bottom) showed 35% 
sequence identity or 58% similarity if conservative amino 
acid replacements were included. Similar alignments were ob- 
tained with the corresponding proteases from Haemophilus 
influenzae and Salmonella typhimurium. All these proteases 
are required for the survival of bacteria t temperatures above 
42°C. We therefore investigated the possibility whether the 
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Fig. 2. Complete nucleotide and derived amino acid sequence of the novel transformation-sensitive protein (databank accession o. Y07921). 
The signal peptidase cleavage site is indicated by an arrow, sequences surrounding the active serine and bistidine residue are underlined; cys- 
teine residues are encircled. 
L56 protein might represent a heat shock protease. However, 
no change in the level of the L56 mRNA was noted when 
human fibroblasts were shifted from 37 to 41°C for 4 h (not 
shown). The HtrA/Do proteases belong to the family of the 
serine proteases since they possess the amino acid sequence 
GNSGGAL in their active site. The corresponding sequence 
GNSGGPL was found in the L56 protein at position 326-332. 
For catalytic activity, the HtrA proteases require, in addition 
to the active serine, a conserved histidine which occurs in the 
E. coli sequence at position 109 (TNNHV). This histidine was 
also found in the human sequence at position 220 (TNAHV). 
Thus, there remains little doubt that the human L56 protein 
represents a functional serine protease. 
The last 40 amino acid residues of the IGF-binding domain 
and the first 20 residues of the protease domain were found to 
share a striking similarity with the Kazal type of serine pro- 
tease inhibitors (Fig. 3, middle) [16]. An alignment of the 
human pancreatic trypsin inhibitor [17] with this region of 
the L56 sequence revealed 32% sequence identity or 53% se- 
quence similarity. With human follistatin which harbors sev- 
eral Kazal domains [18], the identity was even 42% (60% 
similarity). Protease inhibitors of the Kazal type possess a 
conserved tyrosine residue and six cysteine residues which 
are arranged in three disulfide bonds. The tyrosine residue 
and four of the cysteine residues were conserved in the L56 
protein. It is therefore possible that the related segment of the 
L56 protein will fold into a tertiary structure resembling that 
of trypsin inhibitors. 
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Fig. 3. Alignment of the amino acid sequences from the human L56 protein and the human IGFBP-3 (top), the human pancreatic trypsin 
inhibitor (middle) and the HtrA protease from E. coli. Identical residues are boxed; related residues are shaded. 
4. Discussion 
We have isolated the cDNA for a novel transformation- 
sensitive protein from human fibroblasts by subtractive 
cDNA cloning. This protein comprises four distinct domains, 
namely a typical signal peptide, a domain related to IGFBPs, 
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Fig. 4. Domain structure of the novel serine protease. S, signal pep- 
tide; IGFB, domain related to IGFBPs; KI, domain related to the 
Kazal type of protease inhibitors. 
a short linker segment related to the Kazal type of proteinase 
inhibitors and a large domain related to serine proteases (Fig. 
4). 
There is good evidence that the L56 protein represents a 
functional serine protease. Its amino acid sequence shares 58% 
similarity with the HtrA/Do family of proteases from bacteria. 
The HtrA proteases are typical serine proteases which can be 
inhibited by DFP or other trypsin inhibitors [13-15]. In addi- 
tion to the conserved serine residue, they depend on the pres- 
ence of a histidine residue in their catalytic domain. The sim- 
ilarity observed between the human and the bacterial protein 
extends over the entire length of the HtrA sequence and is 
particularly well pronounced in the regions surrounding the 
active serine and histidine residues. 
The high sequence conservation between two proteins from 
bacteria and humans is quite extraordinary. Moderate simi- 
larities have previously been noted with proteins involved in 
fundamental biological processes uch as translation of pro- 
teins at ribosomes or translocation of nascent polypeptides 
across biological membranes [19]. In most cases, however, 
the similarities were confined to the tertiary rather than the 
primary structure of the polypeptides. In spite of this aston- 
ishing similarity, we are convinced that we have not simply 
isolated a bacterial contamination from our cDNA library 
because of three reasons. (1) We have isolated our cDNA 
clones from three independent human libraries. (2) Our clones 
hybridized to a distinct mRNA present in RNA preparations 
from eight different human tissues. (3) Our cDNA sequences 
overlap with several sequence ntries stored in the EST data- 
base of human expressed sequence tags. 
The HtrA protein enables bacteria to survive at elevated 
temperature [13-15]. It seems unlikely that the human protein 
may serve a similar function since its expression is not induced 
by heat shock. Some clues to its function can be deduced from 
its unique primary structure. In contrast o the bacterial pro- 
tein, the human protein contains an additional domain related 
to IGF-binding proteins at its N-terminal end [11,12]. It is 
therefore conceivable that the L56 protease will interact 
with IGFI  or IGFII .  Consequently this domain could play a 
regulatory role in the activation or inhibition of the serine 
protease. This hypothesis is supported by the fact that the 
end of the IGF-binding domain and the beginning of the 
protease domain resemble the Kazal type of protease inhibi- 
tors. Kazal domains occur in serine protease inhibitors (e.g. 
pancreatic trypsin inhibitor) as well as in follistatin-like mol- 
ecules. Recently, it has been proposed that follistatin-like do- 
mains of extracellular matrix proteins may bind and store 
growth factors such as TGF-13 and PDGF [20]. Thus, the 
Kazal domain of the L56 protein might either associate with 
the active site of the serine protease or cooperate with the 
IGF-binding domain in the interaction with growth factors. 
In the literature there is one class of proteases (of unknown 
sequence) that appears to be functionally very similar to the 
L56 protein, namely the proteases that cleave IGF-binding 
proteins [11,12]. It is well documented that the activity of 
IGFI  and IGFI I  is modulated by IGF-binding proteins which 
control the availability of these growth factors for their recep- 
tors. Six IGFBPs occurring in most tissues and body fluids 
have been characterized so far. They bind IGFI  and IGFI I  
with similar affinity and appear to function as a reservoir for 
growth factors. The IGFs are liberated from the complexes by 
specific proteases. The molecular nature, in particular the pri- 
mary structures of these proteases, has remained obscure so 
far. Limited information is available on the biological activity 
of proteases that specifically cleave IGFBP-2 to IGFBP-5 [21- 
26]. All these proteases belong to the family of the serine 
proteases ince they are inhibited by DFP or other serine 
protease inhibitors. Among the four proteases, the one specific 
for IGFBP-4 is most similar to our L56 protein. It is secreted 
by human fibroblasts and its activity is also markedly de- 
creased in SV40 transformed cells. IGFI  and IGFI I  have 
been demonstrated to activate this protease and two mecha- 
nisms have been put forward to explain this activation process 
[21,22]. (1) The growth factors bind directly to the protease, 
thereby inducing proteolytic activity. This mechanism is con- 
sistent with our structural data indicating that the L56 pro- 
tease contains an IGF-binding domain at its N-terminus. (2) 
Binding of IGFs may enhance the susceptibility of the IGFBP 
to proteolytic leavage. This mechanism is not supported by 
our results, but cannot be ruled out either. 
In summary, all our data suggest hat we have cloned a 
novel serine protease related to the proteases for IGFBPs. 
To support our hypothesis it is inevitable now to extend our 
studies to the protein level. Unfortunately, all efforts to ex- 
press our cDNA clones in a bacterial expression system have 
failed so far. The expression of the protein, however, is abso- 
lutely necessary to demonstrate a proteolytic activity of the 
L56 protein and to verify the modulation of this activity by 
IGFs. The expression of the protein should also enable us to 
investigate the role of the novel protease in transformed cells. 
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